longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Yunnan Baiyao: Xiangsha Pingwei Granules have obtained the drug supplementary application approval

Zhitong
Oct 4, 2025 at 01:15 PM

According to Yunnan Baiyao, the sugar-free research project for the Xiangsha Pingwei Granules, jointly undertaken by the Central Research Institute of Yunnan Baiyao Group and the Pharmaceutical Business Group, has received the supplementary application approval from the National Medical Products Administration

Source: Zhitong The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

Yunnan Baiyao

Yunnan Baiyao

000538.SZ

Open

--

High

--

Low

--

Prev Close

--

P/ETTM

--

Market Cap

--

LongbridgeAI